Showing posts with label M Tubeculosis Complex. Show all posts
Showing posts with label M Tubeculosis Complex. Show all posts

Sunday, 17 July 2011

TUBERCULOSIS: secrets of a polymer-building enzyme

Laura Cassiday : July 15, 2011
Solving The Mystery Of Sugar Chain Growth : Assay based on mass spectrometry reveals mechanistic secrets of a polymer-building enzyme

 CDC/ Dr. Ray Butler
IMPENETRABLE WALL Carbohydrate polymers strengthen the cell wall of Mycobacterium tuberculosis to protect the pathogen.Email this article to a friend

Solving The Mystery Of Sugar Chain Growth Assay based on mass spectrometry reveals mechanistic secrets of a polymer-building enzyme.

Mycobacterium tuberculosis, the microbe responsible for tuberculosis, uses an unusually strong cell wall, fortified with a carbohydrate called galactan, to protect itself from harsh environments and its host's immune system. Sugar polymers like galactan are built by enzymes called glycosyltransferases, which add successive sugar molecules to a chain, like beads on a string. Now researchers have developed an assay based on mass spectrometry to answer a long-standing question about the mechanism of these enzymes (J. Am. Chem. Soc., DOI: 10.1021/ja204448t).

Understanding how M. tuberculosis builds galactan could allow researchers to design drugs that interfere with the process, allowing infected people to mount an effective immune response, says Laura Kiessling, a chemical biologist at the University of Wisconsin, Madison.
Kiessling and her colleagues wanted to know whether GlfT2, one of the glycosyltransferases that synthesize galactan, uses what biochemists call a processive or distributive mechanism. Processive enzymes remain bound to the carbohydrate chain as they add monomers, while distributive enzymes fall off the sugar chain after each addition and then bind another chain. Drug designers would like to exploit such a mechanistic understanding in developing enzyme inhibitors, Kiessling says.
To distinguish between the two mechanisms, the researchers designed an assay that detects how often GlfT2 swaps polymer partners during elongation of the sugar chain. Initially, the team exposed GlfT2 to a lipid-linked oligosaccharide that mimics the base of the growing galactan chain. After allowing the enzyme to bind this molecule and start adding sugar monomers, the scientists introduced a deuterium-labeled version of the lipid-linked molecule. After the enzyme continued working to add monomers, the researchers analyzed the reaction products with matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry to measure the length of the sugar chains and to determine whether or not they were labeled with deuterium.
Kiessling expected that if the enzyme was processive, the longest carbohydrate chains would be unlabeled, because the enzyme would tightly latch onto the initial, unlabeled base molecule and wouldn't get distracted when the labeled one appeared. In contrast, a distributive mechanism would produce labeled and unlabeled carbohydrate chains of roughly equal lengths because the two lipid-linked molecules would have equal access to the enzyme each time it fell off a chain.
When Kiessling and her colleagues examined the mass spectrometry data, they found that none of the longest chains were labeled, suggesting to them that GlfT2 used a processive mechanism. Moreover, the researchers quantified the degree of processivity, or the probability that an enzyme bound to the chain would add another sugar before it fell off the chain. They determined that GlfT2's processivity increased as the sugar chain grew, suggesting that the enzyme, like some other polymer-building enzymes, binds more tightly to longer chains.
"This elegant, straightforward approach will be widely used by researchers studying carbohydrate polymerization, and could be applied to other polymers as well," says Todd Lowary, a chemist at the University of Alberta. The knowledge that GlfT2 shows greater affinity for longer sugar chains could be used to design inhibitors for use as antibiotics, he adds, although a crystal structure of the enzyme would better aid drug design.

http://pubs.acs.org/cen/news/89/i29/8929scene3.html

Saturday, 10 July 2010

TUBERCULOSIS: typing the mycobacterium

Background
Tuberculosis (TB) is one of the major public health problems in Zambia. However, information about lineages of M. tuberculosis complex (MTBC) isolates useful for epidemiology investigations is unknown. In this study, we investigated the diversity of MTBC isolates from Ndola, a typical Zambian urbanized city with a documented high HIV prevalence.
Methods
This was part of a prospective cohort study in subjects with sputum smear-positive pulmonary TB. Spoligotyping was used to genotype the MTBC isolates and establish the circulating lineages. The 15-locus Mycobacterial Interspersed Repetitive Units - Variable Number Tandem Repeats (MIRU-VNTR) typing was used to study recent transmission.
Results
A total of 98 different spoligotypes were identified among 273 MTBC isolates. The majority (64.8%) of the isolates belonged to 9 known families, while 96 (35.2%) of the isolates were orphans. While LAM (41.8%) was the largest spoligotype family observed, most of the isolates (87.7%) belonging to the SAF1 family, with a significant portion coming from the T (13.6%), and X (5.9%) families. A few isolates (3.6%) belonged to the CAS, EAI, H, S, X1-LAM9 or U families. MIRU-VNTR typing was highly discriminatory (h=0.988) among the 156 isolates tested in our sample, and increased the discrimination among 82 SAF1 isolates from 6 to 46 distinct patterns. In addition, 3.2% (5/156) of cases with available MIRU-VNTR results harbored more than one MTBC strain.
Conclusions
Our findings show a limited diversity of MTBC in Ndola with a high clustering rate (37.7%), which indicates that recent transmission plays an appreciable role in the dynamics of TB disease in this setting. This conclusion emphasizes the importance of early diagnosis and timely treatment. The results also confirm that MIRU-VNTR typing is suitable for studying the molecular epidemiology of TB in Ndola.

http://www.biomedcentral.com/1471-2334/10/177